表紙
市場調查報告書
商品編碼
1040489

泌尿道感染的全球市場-2021∼2027年

Global Urinary Tract Infection Market 2021-2027

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球泌尿道感染的市場規模,在預測期間內預計以約15.8%大幅度的年複合成長率成長。

複雜的泌尿道感染的盛行率,由於藥物抗性菌增加和抗生素的過剩使用,預計今後上升。

本報告提供全球泌尿道感染市場相關調查分析,市場概要與洞察,競爭情形,市場決策要素,各檢驗類型、適應症、終端用戶分析,地區分析,企業簡介等資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和目前市場趨勢
  • 法規

第3章 競爭情形

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
  • 重要的策略分析
  • COVID-19對主要企業的影響

第4章 市場決策要素

  • 促進因素
  • 阻礙因素
  • 市場機會

第5章 市場區隔

  • 檢驗各類型
    • 生物化學的泌尿道感染
    • 顯微鏡的泌尿道感染
    • 流式細胞技術泌尿道感染
  • 各適應症
    • 併發症的泌尿道感染
    • 非併發症的泌尿道感染
    • 神經原因性膀胱炎
  • 各終端用戶
    • 醫院和診所
    • 家庭醫療保健

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 其他地區

第7章 企業簡介

  • Acon Laboratories, Inc.
  • ARKRAY Group
  • AstraZeneca PLC
  • Bayer AG
  • Danaher Corp.
  • Becton, Dickinson and Co.
  • Biomerieux S.A.
  • Bio-Rad Laboratories Inc.
  • Biotronik SE & Co. KG
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Siemens AG
  • Shionogi & Co., Ltd.
  • Sysmex Europe GmbH.
  • Teva Pharmaceutical Industries Ltd.
  • Watson's Personal Care Pte. Ltd.
目錄
Product Code: OMR2024040

Global Urinary Tract Infection Market Size, Share &Trends Analysis Report By Test Type (Biochemical Urinary Tract Infection, Microscopic Urinary Tract Infection, Flow Cytometric Urinary Tract Infection) By Indication (Complicated Urinary Tract Infection, Uncomplicated Urinary Tract Infection, Neurogenic Bladder Infections), End-User (Hospitals &Clinics, and Home Healthcare) Forecast Period 2021-2027

The global market for Urinary Tract Infections is projected to have a considerable CAGR of around 15.8% during the forecast period. The prevalence of complex UTI is predicted to rise in the future due to the rise in drug-resistant bacteria and overuse of antibiotics. A vast majority of physicians prescribe quinolones to treat complicated UTI cases. Cephalosporin is the second-most common drug prescribed for complicated UTI cases. According to the American Academy of Family Physicians (AAFP), kidney stones are a common disease, with an annual incidence of eight cases per 1,000 individuals. Furthermore, around 13% of men and 7% of women may develop a kidney stone during their lifetime, and the total incidence of urinary retention in the US is 4.5 to 6.8 per 1,000 males per year. Overall, the prevalence of complicated UTI is expected to increase over the projected period, owing to rising bacterial resistance in UTI patients and a higher recurrence rate.

The global urinary tract infection market is segmented based on test type, indication, and end-user On the basis of test type, the market is segmented into biochemical urinary tract infection, microscopic urinary tract infection, and flow cytometric urinary tract infection. Based on indication, the market is segmented into complicated urinary tract infection, uncomplicated urinary tract infection, neurogenic bladder infections. Further on the basis of end-user, the market is segmented into hospitals &clinics, and home healthcare

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is estimated to dominate the market as the region expects a significant increase in their investment towards innovation and technological advancements therapeutic products and diagnostics that will aid in the global growth of the urinary tract infection market.

The key players of the market include AstraZeneca PLC, Bayer AG, Danaher Corp., Becton, Dickinson and Co., Biotronik SE &Co. KG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Pfizer Inc., Siemens AG, among others. These market players adopt various strategies such as product launches, partnerships, collaborations, mergers, and acquisitions to sustain a strong position in the market. In September 2020, Spero Therapeutics, Inc. a multi-asset clinical-stage biopharmaceutical company announced positive topline results from ADAPT-PO, the pivotal Phase 3 clinical trial evaluating Spero's oral antibiotic candidate, tebipenem HBr, for the treatment of adults with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). The global Phase 3 ADAPT-PO clinical trial compared the safety and effectiveness of oral tebipenem HBr versus IV ertapenem. Results demonstrated that tebipenem HBr was non-inferior compared to ertapenem with respect to the trial's primary endpoint, overall response (combined clinical cure plus microbiologic eradication) at the test-of-cure (TOC) visit in the microbiological-intent-to-treat (micro-ITT) population.

Research Methodology

The market study of the global Urinary Tract Infections market is incorporated by extensive primary and secondary research conducted by the research team at OMR Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

Financial reports of companies involved in the market

Whitepapers, research papers, and news blogs

Company websites and their product catalog

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Ostomy Urinary Tract Infections Market Research and Analysis by Test type

Global Ostomy Urinary Tract Infections Market Research and Analysis by Indication

Global Ostomy Urinary Tract Infections Market Research and Analysis by End-user

The Report Covers

Comprehensive research methodology of the global Urinary Tract Infections market

This report also includes a detailed and extensive market overview with key analyst insights

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations

Analysis of regional regulations and other government policies impacting the global Urinary Tract Infections market

Insights about market determinants that are stimulating the global Urinary Tract Infections market

Detailed and extensive market segments with the regional distribution of forecasted revenues

Extensive profiles and recent developments of market players

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Urinary Tract Infection Industry
  • Recovery Scenario of Global Urinary Tract Infection Industry
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Regulations

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on key players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Urinary Tract Infection Market by Test Type
    • 5.1.1. Biochemical Urinary Tract Infection
    • 5.1.2. Microscopic Urinary Tract Infection
    • 5.1.3. Flow Cytometric Urinary Tract Infection
  • 5.2. Global Urinary Tract Infection market by Indication
    • 5.2.1. Complicated Urinary Tract Infection
    • 5.2.2. Uncomplicated Urinary Tract Infection
    • 5.2.3. Neurogenic Bladder Infections
  • 5.3. Global Urinary Tract Infection market by End-User
    • 5.3.1. Hospitals and Clinics
    • 5.3.2. Home Healthcare

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Acon Laboratories, Inc.
  • 7.2. ARKRAY Group
  • 7.3. AstraZeneca PLC
  • 7.4. Bayer AG
  • 7.5. Danaher Corp.
  • 7.6. Becton, Dickinson and Co.
  • 7.7. Biomerieux S.A.
  • 7.8. Bio-Rad Laboratories Inc.
  • 7.9. Biotronik SE & Co. KG
  • 7.10. Boehringer Ingelheim GmbH
  • 7.11. F. Hoffmann-La Roche Ltd.
  • 7.12. GlaxoSmithKline PLC
  • 7.13. Novartis International AG
  • 7.14. Pfizer Inc.
  • 7.15. Sanofi S.A.
  • 7.16. Siemens AG
  • 7.17. Shionogi & Co., Ltd.
  • 7.18. Sysmex Europe GmbH.
  • 7.19. Teva Pharmaceutical Industries Ltd.
  • 7.20. Watson's Personal Care Pte. Ltd.

LIST OF TABLES

  • 1. GLOBAL URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY TEST TYE, 2020-2027 ($ MILLION)
  • 2. GLOBAL BIOCHEMICAL URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 3. GLOBAL MICROSCOPIC URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL FLOW CYTOMETRIC URINARY TRACT INFECTIONMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

5. GLOBAL URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY INDICATION,

  • 6. GLOBAL COMPLICATED URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
  • 7. GLOBAL UNCOMPLICATED URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL NEUROGENIC BLADDER INFECTIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 10. GLOBAL HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL HOME HEALTHCARE MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 12. GLOBAL URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 13. NORTH AMERICAN URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 14. NORTH AMERICAN URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2020-2027 ($ MILLION)
  • 15. NORTH AMERICAN URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
  • 16. NORTH AMERICAN URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 17. EUROPEAN URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 18. EUROPEAN URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2020-2027 ($ MILLION)
  • 19. EUROPEAN URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
  • 20. EUROPEAN URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 21. ASIA-PACIFIC URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 22. ASIA-PACIFIC URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2020-2027 ($ MILLION)
  • 23. ASIA-PACIFIC URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
  • 24. ASIA-PACIFIC URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 25. REST OF THE WORLD URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 26. REST OF THE WORLD URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY TEST TYPE 2020-2027 ($ MILLION)
  • 27. REST OF THE WORLD URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
  • 28. REST OF THE WORLD URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)

LIST OF FIGURES

1. IMPACT OF COVID-19 ON GLOBAL URINARY TRACT INFECTION MARKET, 2020-2027 (% MILLION)

2. IMPACT OF COVID-19 ON GLOBAL URINARY TRACT INFECTION MARKET BY SEGMENT, 2020-2027 (% MILLION)

  • 3. RECOVERY OF GLOBAL URINARY TRACT INFECTION MARKET, 2020-2027 (%)
  • 4. GLOBAL URINARY TRACT INFECTION MARKET SHARE BY TEST TYPE, 2020 VS 2027 (%)
  • 5. GLOBAL URINARY TRACT INFECTION MARKET SHARE BY INDICATION, 2020 VS 2027 (%)
  • 6. GLOBAL URINARY TRACT INFECTION MARKET SHARE BY END-USER 2020 VS 2027 (%)
  • 7. GLOBAL URINARY TRACT INFECTION MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 8. GLOBAL BIOCHEMICAL URINARY TRACT INFECTION MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL MICROSCOPIC URINARY TRACT INFECTION MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 10. GLOBAL FLOW CYTOMETRIC URINARY TRACT INFECTION MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 11. GLOBAL COMPLICATED URINARY TRACT INFECTION MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 12. GLOBAL UNCOMPLICATED URINARY TRACT INFECTION MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 13. GLOBAL NEUROGENIC BLADDER INFECTIONS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 14. GLOBAL HOSPITALS AND CLINICS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 15. GLOBAL HOME HEALTHCARE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 16. US URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
  • 17. CANADA URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
  • 18. UK URINARY TRACT INFECTION AND MICROSCOPIC URINARY TRACT INFECTIONMARKET SIZE, 2020-2027($ MILLION)
  • 19. FRANCE URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
  • 20. GERMANY URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
  • 21. ITALY URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
  • 22. SPAIN URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
  • 23. REST OF EUROPE URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
  • 24. INDIA URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
  • 25. CHINA URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
  • 26. JAPAN URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
  • 27. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
  • 28. REST OF ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
  • 29. REST OF THE WORLD URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)